Compare Amphastar Pharmaceuticals Inc (AMPH) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while YieldMax TSLA Option Income Strategy ETF trades at $21.87. The key difference: Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMPH | TSLY | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $48.25 |
52-Week Low | $16.87 | $20.49 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
TSLY trades at $21.55, up 1.03% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF maintains a high dividend yield strategy, with recent weekly distributions averaging around $0.28 per share. Support and resistance levels are tightly clustered near the current price, indicating limited near-term price movement potential.
The outlook for TSLY is cautious due to capped upside from its option income structure and dependence on Tesla's volatility. Risks include missed participation in Tesla rallies and high distribution volatility. Analyst sentiment has shifted to neutral, reflecting concerns over sustainable yield and growth constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
